Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Ann R Coll Surg Engl ; : e1-e3, 2018 Aug 16.
Article in English | MEDLINE | ID: mdl-30112944

ABSTRACT

Surgical management of oesophageal and gastro-oesophageal junction malignancies is one of the most challenging situations confronting the surgeon. Attaining a complete circumferential resection margin of lower-third oesophageal and gastro-oesophageal junction locally advanced carcinomas requires en-bloc resection of the hiatus and all the peri-oesophageal tissue and pleura. This results in an increased risk of herniation of the abdominal organs through the enlarged hiatus, which carries significant risk of morbidity and mortality. The incidence of this complication is higher than has been reported. Surgical management of symptomatic hernias is the standard treatment while criteria for managing asymptomatic hernias are less clear. We report a rare case of a late mediastinal herniation of the pancreas and bile duct, leading to obstructive jaundice following oesophagectomy which was treated successfully in our unit.

2.
World J Surg ; 42(8): 2507-2511, 2018 08.
Article in English | MEDLINE | ID: mdl-29372375

ABSTRACT

BACKGROUND: Leaks from the upper gastrointestinal tract often pose a management challenge, particularly when surgical treatment has failed or is impossible. Vacuum therapy has revolutionised the treatment of wounds, and its role in enabling and accelerating healing is now explored in oesophagogastric surgery. METHODS: A piece of open cell foam is sutured around the distal end of a nasogastric tube using a silk suture. Under general anaesthetic, the foam covered tip is placed endoscopically through the perforation and into any extra-luminal cavity. Continuous negative pressure (125 mmHg) is then applied. Re-evaluation with change of the negative pressure system is performed every 48-72 h depending on the clinical condition. Patients are fed enterally and treated with broad-spectrum antibiotics and anti-fungal medication until healing, assessed endoscopically and/or radiologically, is complete. RESULTS: Since April 2011, twenty one patients have been treated. The cause of the leak was postoperative/iatrogenic complications (14 patients) and ischaemic/spontaneous perforation (seven patients). Twenty patients (95%) completed treatment successfully with healing of the defect and/or resolution of the cavity and were subsequently discharged from our care. One patient died from sepsis related to an oesophageal leak after withdrawing consent for further intervention following a single endoluminal vacuum (E-Vac) treatment. In addition, two patients who were successfully treated with E-Vac for their leak subsequently died within 90 days of E-Vac treatment from complications that were not associated with the E-Vac procedure. In two patients, E-Vac treatment was complicated by bleeding. The median number of E-Vac changes was 7 (range 3-12), and the median length of hospital stay was 35 days (range 23-152). CONCLUSIONS: E-Vac therapy is a safe and effective treatment for upper gastrointestinal leaks and should be considered alongside more established therapies. Further research is now needed to understand the mechanism of action and to improve the ease with which E-Vac therapy can be delivered.


Subject(s)
Esophagus/surgery , Negative-Pressure Wound Therapy , Postoperative Complications/surgery , Aged, 80 and over , Female , Humans , Length of Stay , Middle Aged , Negative-Pressure Wound Therapy/adverse effects , Negative-Pressure Wound Therapy/methods , Postoperative Complications/mortality , Sepsis/etiology , Treatment Outcome , Vacuum , Wound Healing
3.
Ann R Coll Surg Engl ; 100(1): e15-e17, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29046081

ABSTRACT

Delayed gastrointestinal bleeding in the context of a gastric fistula is a very rare complication of longitudinal sleeve gastrectomy. We report the case of a patient who presented with massive gastrointestinal bleeding from a pseudoaneurysm arising from the splenic artery following complications after a longitudinal sleeve gastrectomy several months previously. The case was successfully managed with angiographic embolisation and we present our experience with recommendations for managing this rare but life-threatening complication.


Subject(s)
Aneurysm, False , Gastrectomy/adverse effects , Gastric Fistula , Gastrointestinal Hemorrhage , Splenic Artery , Female , Humans , Middle Aged , Splenic Artery/diagnostic imaging , Splenic Artery/pathology , Splenic Artery/surgery
4.
Ann R Coll Surg Engl ; 99(2): e44-e46, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27659378

ABSTRACT

Robotic surgery is an established therapy for localised prostate cancer and is replacing conventional laparoscopic prostatectomy in developed countries. Port-site hernia is a recognised, albeit small, risk following laparoscopic or robotic surgery. We report a case of spontaneous rupture of the right hemidiaphragm following robotic prostatectomy.


Subject(s)
Diaphragm/injuries , Muscular Diseases/etiology , Postoperative Complications , Prostatectomy/adverse effects , Robotic Surgical Procedures/adverse effects , Rupture, Spontaneous/etiology , Aged , Humans , Male
5.
Ann R Coll Surg Engl ; 99(2): e58-e59, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27791422

ABSTRACT

Despite the decreasing popularity of gastric banding, a large number of patients still have a band in situ. Although immediate postoperative complications are relatively rare, long-term complications of gastric banding are more common but are not reported to occur after band removal. We report a case of gastric volvulus and subsequent ischaemic perforation in a patient shortly after band removal, resulting in emergency laparotomy and total gastrectomy. Severe continuing pain persisting after band deflation and even gastric band removal should be treated as an emergency and urgent investigation should not be delayed.


Subject(s)
Bariatric Surgery/adverse effects , Device Removal/adverse effects , Stomach Volvulus , Stomach , Bariatric Surgery/instrumentation , Bariatric Surgery/methods , Female , Humans , Middle Aged , Stomach/diagnostic imaging , Stomach/pathology , Stomach/surgery
6.
Dis Esophagus ; 21(3): 201-6, 2008.
Article in English | MEDLINE | ID: mdl-18430099

ABSTRACT

The Medical Research Council trial for oesophageal cancer (OEO2) trial demonstrated a clear survival benefit from neoadjuvant chemotherapy in resectable esophageal carcinoma. Since February 2000 it has been our practice to offer this chemotherapy regime to patients with T2 and T3 or T1N1 tumors. We analyzed prospectively collected data of patients who received neoadjuvant chemotherapy prior to esophageal resection under the care of a single surgeon. Complications of treatment and overall outcomes were evaluated. A total of 194 patients had cisplatin and 5-fluorouracil prior to esophageal resection. Six patients (5.7%) had progressive disease and were inoperable (discovered in four at surgery). During chemotherapy one patient died and one perforated (operated immediately). Complications including severe neutropenia, coronary artery spasm, renal impairment and pulmonary edema led to the premature cessation of chemotherapy in 12 patients (6.2%). A total of 182 patients with a median age of 63 (range 30-80), 41 squamous and 141 adenocarcinomas underwent surgery. Operations were 91 left thoracoabdominal (50%), 45 radical transhiatal (25%), 40 Ivor-Lewis (22%) and six stage three (3%), and 78.6% had microscopically complete (R0) resections. Median survival was 28 months with 77.3% surviving for 1 year and 57.7% for 2 year. In hospital mortality was 5.5% and anastomotic leak rate 7.7%. A radical surgical approach to the primary tumor in combination with OEO2 neoadjuvant chemotherapy has led to a high R0 resection rate and good survival with acceptable morbidity and mortality.


Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/surgery , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/surgery , Esophageal Neoplasms/drug therapy , Esophageal Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Chemotherapy, Adjuvant , Female , Humans , Male , Middle Aged , Prospective Studies , Survival Rate
7.
Br J Surg ; 95(2): 191-4, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17948302

ABSTRACT

BACKGROUND: The significance of circumferential resection margin (CRM) involvement in oesophageal cancer surgery is controversial. This study investigated the relationship between CRM involvement, locoregional recurrence and survival, after surgery alone or with neoadjuvant chemotherapy. METHODS: Patients operated on by one surgeon at a tertiary referral centre between October 1997 and May 2004 were identified from a prospective database. RESULTS: Some 242 patients underwent oesophagectomy; 91 had surgery alone, 142 had neoadjuvant chemotherapy and nine neoadjuvant chemoradiotherapy. Among patients with histologically confirmed T3 tumours, 26 (55 per cent) of 47 who underwent surgery alone had CRM involvement, compared with 27 (31 per cent) of 88 patients who completed two cycles of neoadjuvant chemotherapy (P = 0.005). Thirty-seven (42 per cent) of 89 patients with a negative CRM developed locoregional recurrence, compared with 33 (59 per cent) of 56 with a positive margin (P = 0.032); median survival was 28 and 12 months respectively (P < 0.001). Cox multivariable regression analysis identified CRM involvement as an independent prognostic factor (P = 0.006). CONCLUSION: A positive CRM is an independent predictor of overall survival after oesophageal cancer resection. There has been a significant decrease in CRM involvement with the introduction of neoadjuvant chemotherapy.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Squamous Cell/drug therapy , Esophageal Neoplasms/drug therapy , Adenocarcinoma/mortality , Adenocarcinoma/surgery , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/surgery , Chemotherapy, Adjuvant , Cisplatin/administration & dosage , Disease-Free Survival , Esophageal Neoplasms/mortality , Esophageal Neoplasms/surgery , Female , Fluorouracil/administration & dosage , Humans , Lymphatic Metastasis , Male , Middle Aged , Neoadjuvant Therapy , Neoplasm Recurrence, Local/etiology , Neoplasm Recurrence, Local/mortality , Prospective Studies , Treatment Outcome
8.
Surgeon ; 5(3): 149-53, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17575668

ABSTRACT

BACKGROUND AND AIMS: It has been reported that gastric gastrointestinal stromal tumours (GIST) are aggressive, rare and difficult to treat. Some have advocated radical resection as the only potential cure. We present data to support treatment of gastric GISTs with a limited surgical approach and minimal morbidity. Furthermore, we propose that surveillance for recurrence is unnecessary based upon the follow-up of a cohort of patients with gastric GISTs. METHODS: Database and case notes analysis of 20 patients diagnosed with gastric GIST (1998-2004) and managed by one surgeon in a single centre over seven years. Main outcome measures were inpatient adverse events, positive resection margins and symptom free survival. OUTCOMES: Three cases have been managed with surveillance only. Successful resection was performed in 17 patients without mortality. No patient had positive margins on histological assessment. Fifteen out of seventeen samples were positive for the c-Kit proto-oncogene (CD117) and 14117 positive for CD34. Only two patients required en-bloc resections due to the tumour size and involvement of adjacent structures. One patient developed metastatic disease during follow-up of 19-86 months. CONCLUSIONS: We recommend local excision of gastric GISTs to allow macroscopically clear margins. This policy then allows symptomatic follow-up due to the indolent nature of the majority of the tumours resected. A tailored follow-up with endoscopy and radiological imaging has been advocated by others but appears unnecessary in most cases. Imatinib (anti c-Kit) can now be offered to patients presenting with recurrent GIST, if further surgery is deemed inappropriate.


Subject(s)
Gastrointestinal Stromal Tumors/surgery , Stomach Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Antigens, CD34/blood , Antineoplastic Agents/therapeutic use , Benzamides , Biomarkers, Tumor/blood , Disease-Free Survival , Female , Follow-Up Studies , Gastrectomy , Gastrointestinal Stromal Tumors/pathology , Humans , Imatinib Mesylate , Male , Middle Aged , Neoplasm Recurrence, Local , Pancreatectomy , Piperazines/therapeutic use , Population Surveillance , Proto-Oncogene Mas , Proto-Oncogene Proteins c-kit/blood , Pyrimidines/therapeutic use , Splenectomy , Stomach Neoplasms/pathology , Thoracic Neoplasms/drug therapy , Thoracic Neoplasms/secondary , Thoracic Wall/pathology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...